·PIB·15 marks·250–350 words

Examine how the BioE3 policy and biofoundry infrastructure can make India a global biomanufacturing hub. What are the regulatory and biosafety challenges?

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. How BioE3 and biofoundries can build a hub
  2. Regulatory and biosafety challenges

The Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment and Employment) Policy in August 2024 to promote high-performance biomanufacturing [1]. India's bioeconomy grew from $10 billion in 2014 to $165.7 billion in 2024, and the target is $300 billion by 2030 [2]. BioE3 and biofoundries supply the base for that growth, but weak regulation and biosafety gaps could slow it.

How BioE3 and biofoundries can build a hub

  • Focused sectors: bio-based chemicals and enzymes, precision biotherapeutics, climate-resilient agriculture, carbon capture, and marine and space biomanufacturing [1].
  • Lab-to-factory chain: biofoundries, biomanufacturing hubs and Bio-AI hubs carry discoveries through to pilot and pre-commercial scale [2].
  • First biofoundry: India's first biofoundry for microbial biomanufacturing is at ICGEB New Delhi, which the Department of Biotechnology (DBT) supports [3].
  • Global links: ICGEB's Trieste component gives access to a new BSL-3 laboratory and high-throughput screening [3].
  • Science diplomacy: 67 researchers from 22 countries trained at ICGEB New Delhi in 2023–26 [3]. This makes India a partner for the Global South.
  • The limit: reaching $300 billion needs about 10% growth every year [2]. But India's research spending (GERD) is only about 0.64% of GDP, against a long-held goal of 2% [4].

Regulatory and biosafety challenges

  • Dual-use risk: BSL-3 work on infectious agents [3] helps prepare for pandemics. The same knowledge could be misused, so access to materials and results must be tightly controlled.
  • Genome-edited crops: ICGEB works on genome-edited crops [3]. Lighter rules for some edits mean less public testing, which weakens public trust.
  • Scale-up approvals: new bio-products face slow approvals spread across several regulators. This delays the move from a working lab process to a product on the market.
  • IP and accountability: shared multilateral research makes it hard to divide patents fairly. There is also no public data on what India pays ICGEB or gets back [3].

BioE3 gives India the policy and the infrastructure to become a biomanufacturing hub, but trust and private investment will decide whether it gets there. DBT and BIRAC should feed processes proven at biofoundries into the BioE3 hubs, set up a single-window, risk-based approval system, enforce strict dual-use rules, and publish a yearly report on ICGEB results. Done together, these steps can make India's bioeconomy safe and globally competitive, in line with SDG 9 (industry, innovation and infrastructure).

Sources

  1. 1PIB: Cabinet Approves Vigyan Dhara and BioE3 Initiatives (Aug 2024): BioE3 approval and its focus sectors
  2. 2PIB: India – A Global Bioeconomy Powerhouse (Sep 2025): bioeconomy growth figures, the $300 billion target, biofoundries and biomanufacturing/Bio-AI hubs
  3. 3PIB Press Release: Dr. Jitendra Singh visits ICGEB Trieste (Nov 2026): ICGEB biofoundry, DBT support, BSL-3 and screening facilities, 67 researchers from 22 countries, genome-edited crops
  4. 4PRS Legislative Research: Demand for Grants 2024-25 Analysis – Science and Technology: GERD of 0.64% of GDP (2020-21) against the 2% goal

More from this note